A combination of Novo Nordisk's insulin products degludec and aspart helped prevent hypoglycemic events during the day and at night in type 1 and type 2 diabetes patients, according to a study presented at the World Diabetes Congress. Researchers also found that the combination lowered fasting plasma glucose.

Full Story:
Drug Store News

Related Summaries